Literature DB >> 28278071

The expression of asparaginyl endopeptidase promotes growth potential in epithelial ovarian cancer.

Qinyi Zhu1, Meiling Tang1, Xipeng Wang1.   

Abstract

Epithelial ovarian cancer (EOC) is the most common and lethal cancer-related death among females in the world. Asparaginyl endopeptidase (AEP) is a member of C13 family peptidases and expressed in the extracellular matrix and tumor cells. The aim of this article is to explore the function of asparaginyl endopeptidase in epithelial ovarian cancer. The expression of AEP was examined in 20 EOC samples, 3 EOC metastasis samples, 6 fallopian tube metastasis samples, 4 peritoneum metastasis samples and 20 benign ovarian tumor samples by immunohistochemistry. The expression of AEP was also evaluated in serum and ascites of EOC patients by elisa. And we used a lentiviral vector to overexpress AEP in human epithelial ovarian cancer cell lines SKOV3ip and detected the function of AEP-SKOV3ip cells both in vitro and in vivo. The growth of AEP-SKOV3ip cells was observed by MTT, migration and tube formation assays in vitro. Additionally, the subcutaneous mice model was used to identify the tumor growth and metastasis in vivo. Mice tumors were stained for CD31 to determine the microvessel density (MVD). We demonstrated that AEP was highly expressed in the EOC patient tissues and ascites. The AEP transfected SKOV3ip cells could both promote tumor growth in vitro and in vivo. The MVD in AEP-SKOV3ip group was higher than that in NC-SKOV3ip group. Therefore, our results demonstrated that AEP could induce EOC growth and progressionboth in vitro and in vivo.

Entities:  

Keywords:  Animal model; asparaginyl endopeptidase; epithelial ovarian cancer; microvessel density

Mesh:

Substances:

Year:  2017        PMID: 28278071      PMCID: PMC5450730          DOI: 10.1080/15384047.2017.1294290

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  23 in total

Review 1.  Recurrent epithelial ovarian cancer: an update on treatment.

Authors:  Olivia W Foley; J Alejandro Rauh-Hain; Marcela G del Carmen
Journal:  Oncology (Williston Park)       Date:  2013-04       Impact factor: 2.990

2.  Nucleoplasmic calcium regulates cell proliferation through legumain.

Authors:  Viviane Andrade; Mateus Guerra; Camila Jardim; Flavia Melo; Wamberto Silva; Jose M Ortega; Marie Robert; Michael H Nathanson; Fatima Leite
Journal:  J Hepatol       Date:  2011-01-13       Impact factor: 25.083

3.  A census of human soluble protein complexes.

Authors:  Pierre C Havugimana; G Traver Hart; Tamás Nepusz; Haixuan Yang; Andrei L Turinsky; Zhihua Li; Peggy I Wang; Daniel R Boutz; Vincent Fong; Sadhna Phanse; Mohan Babu; Stephanie A Craig; Pingzhao Hu; Cuihong Wan; James Vlasblom; Vaqaar-un-Nisa Dar; Alexandr Bezginov; Gregory W Clark; Gabriel C Wu; Shoshana J Wodak; Elisabeth R M Tillier; Alberto Paccanaro; Edward M Marcotte; Andrew Emili
Journal:  Cell       Date:  2012-08-31       Impact factor: 41.582

4.  Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells.

Authors:  Fernando E Sepulveda; Sophia Maschalidi; Renaud Colisson; Lea Heslop; Cristina Ghirelli; Emna Sakka; Ana-Maria Lennon-Duménil; Sebastian Amigorena; Lucien Cabanie; Bénédicte Manoury
Journal:  Immunity       Date:  2009-10-29       Impact factor: 31.745

5.  Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis.

Authors:  Yingying Lin; Chongyang Wei; Yuan Liu; Yongming Qiu; Cheng Liu; Fang Guo
Journal:  Cancer Sci       Date:  2013-06-19       Impact factor: 6.716

6.  Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer.

Authors:  Rosemary D Cress; Yingjia S Chen; Cyllene R Morris; Megan Petersen; Gary S Leiserowitz
Journal:  Obstet Gynecol       Date:  2015-09       Impact factor: 7.661

7.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

8.  PRAME expression and promoter hypomethylation in epithelial ovarian cancer.

Authors:  Wa Zhang; Carter J Barger; Kevin H Eng; David Klinkebiel; Petra A Link; Angela Omilian; Wiam Bshara; Kunle Odunsi; Adam R Karpf
Journal:  Oncotarget       Date:  2016-07-19

9.  HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.

Authors:  J R Ribeiro; C Schorl; N Yano; N Romano; K K Kim; R K Singh; R G Moore
Journal:  J Ovarian Res       Date:  2016-05-17       Impact factor: 4.234

10.  Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.

Authors:  Ming-Mo Hou; Zhijie Wang; Filip Janku; Sarina Piha-Paul; Aung Naing; David Hong; Shannon Westin; Robert L Coleman; Anil K Sood; Apostolia M Tsimberidou; Vivek Subbiah; Jennifer Wheler; Ralph Zinner; Karen Lu; Funda Meric-Bernstam; Siqing Fu
Journal:  Oncotarget       Date:  2016-06-07
View more
  4 in total

1.  Cleavage of tropomodulin-3 by asparagine endopeptidase promotes cancer malignancy by actin remodeling and SND1/RhoA signaling.

Authors:  Binghong Chen; Mengying Wang; Junjun Qiu; Keman Liao; Wenrui Zhang; Qi Lv; Chunhui Ma; Zhongrun Qian; Zhonggang Shi; Rong Liang; Yan Lin; Jiazhou Ye; Yongming Qiu; Yingying Lin
Journal:  J Exp Clin Cancer Res       Date:  2022-06-28

Review 2.  The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.

Authors:  Cailin O'Connell; Sabrina VandenHeuvel; Aparna Kamat; Shreya Raghavan; Biana Godin
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

Review 3.  The Mechanism of Asparagine Endopeptidase in the Progression of Malignant Tumors: A Review.

Authors:  Wenrui Zhang; Yingying Lin
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

4.  Identification and analysis of long non-coding RNA related miRNA sponge regulatory network in bladder urothelial carcinoma.

Authors:  Jiawu Wang; Chengyao Zhang; Yan Wu; Weiyang He; Xin Gou
Journal:  Cancer Cell Int       Date:  2019-12-03       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.